Stock Market News For Jan 23, 2018
Major benchmarks hit record highs on Monday after the Senate gave its consent to pass a Bill that ends the current government shutdown. Meanwhile, biotech sector rallied following major biotech merger deals. This led the Nasdaq higher which ended at a record. The Dow and the S&P also ended in record territory.
The Dow Jones Industrial Average (DJI) increased 0.6%, to close at 26,214.60. The S&P 500 rose 0.8% to close at 2,832.97. The tech-laden Nasdaq Composite Index closed at 7,408.03, gaining 1%. The fear-gauge CBOE Volatility Index (VIX) decreased 3.6% to close at 10.87. A total of around 6.56 billion shares were traded on Monday, higher than the last 20-session average of 6.34 billion shares. Advancers outnumbered decliners on the NYSE by a 1.70-to-1 ratio. On Nasdaq, a 1.38-to-1 ratio favored advancing issues.
Biotech ETF Surges, Pushes Nasdaq Higher
The iShares Nasdaq Biotechnology ETF (IBB) surged 3.1% on Monday following a couple of merger deals in the biotech sector worth billions of dollars. Touted to be the largest biotech ETF, iShares Nasdaq Biotechnology is trading at its highest levels since October 2017.
Shares of Juno Therapeutics, Inc. JUNO skyrocketed 26.8% on Monday after it entered into an agreement with Celgene Corp. CELG to be purchased for a whopping $9 billion. In other deal news, Bioverativ Inc. BIVV agreed to purchase Sanofi SNY for $12 billion. Following such news, shares of Bioverativ rallied 63%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
These developments led to broad based gains for the biotech sector and also pushed the Nasdaq higher. The tech-laden index surged 71.7 points to end the session at an all-time high. Gains for Nasdaq were further supported by a surge of 3.2% in the shares of Netflix NFLX.
Dow and S&P 500 Post Record Closes
The S&P 500 gained 22.7 points to hit a record high. Of the 11 major segments of the S&P 500, 10 ended in the green, with consumer discretionary shares leading the advancers. The Energy Select Sector SPDR ETF (XLE) and Consumer Discret Sel Sect SPDR ETF (XLY) gained 2.2% and 1.1%, respectively.
The Dow amassed 142.9 points to finish at a record close. Such gains were rather broad based and followed the Senate’s decision to approve a bill that would end the government shutdown.
Senate Approves a Bill to Prevent Shutdown
On Monday, the Senate approved a Bill which paved way for the ongoing government shutdown to end. The House had already passed a one-month spending Bill on Jan 18 to keep the government funded up until Feb 16, 2018. However, the Bill did not find much favor in the Senate and therefore could not reach the 60-vote mark to clear the Senate. The Senate adjourned without further voting for a final outcome on Thursday.
The funding to keep the government funded ended on Saturday, leading to a shutdown. This shutdown stretched through Monday after lawmakers in the United States failed to reach a resolution on the issue. This was due to negotiations related to immigrations, discussions over which bothered the Republican-led Congress for most of Sunday.
Stocks That Made Headlines
AIG to Buy Validus, Expand Reach in Reinsurance Business
American International Group Inc. AIG has agreed to buy Bermuda based reinsurer, Validus Holdings Ltd. (Validus). The deal should see light by mid-2018. (Read More)
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Netflix, Inc. (NFLX) : Free Stock Analysis Report
Sanofi (SNY) : Free Stock Analysis Report
American International Group, Inc. (AIG) : Free Stock Analysis Report
Celgene Corporation (CELG) : Free Stock Analysis Report
Juno Therapeutics, Inc. (JUNO) : Free Stock Analysis Report
BIOVERATIV INC (BIVV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
